Company Filing History:
Years Active: 2020-2024
Title: Norihiro Watanabe: Innovator in Oncolytic Virotherapy
Introduction
Norihiro Watanabe is a prominent inventor based in Houston, Texas, known for his significant contributions to the field of cancer therapy. He holds three patents that focus on innovative approaches to oncolytic virotherapy, which harnesses the power of viruses to target and destroy cancer cells.
Latest Patents
Watanabe's latest patents include groundbreaking work on oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules. This patent details a combination therapy for cancer that utilizes an oncolytic virus, a virus comprising nucleic acid encoding an immunomodulatory factor, and at least one cell with a chimeric antigen receptor (CAR) specific for a cancer cell antigen. Notably, the virus may encode IL-12 and/or an antagonist anti-PD-L1 antibody. Another patent by Watanabe also focuses on oncolytic virotherapy and immunotherapy, emphasizing the same combination therapy approach to enhance cancer treatment efficacy.
Career Highlights
Watanabe is affiliated with Baylor College of Medicine, where he conducts research and develops innovative therapies aimed at improving cancer treatment outcomes. His work is characterized by a commitment to advancing medical science through the application of cutting-edge technology and research methodologies.
Collaborations
Watanabe collaborates with esteemed colleagues such as Masataka Suzuki and Amanda Rosewell Shaw, contributing to a dynamic research environment that fosters innovation and discovery in cancer therapy.
Conclusion
Norihiro Watanabe's contributions to oncolytic virotherapy represent a significant advancement in cancer treatment. His innovative patents and collaborative efforts at Baylor College of Medicine highlight his dedication to improving patient outcomes through scientific research.